Skip to main content
main-content

29-05-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: The HER2CLIMB trial

Nancy Lin presents the latest findings from the HER2CLIMB trial, reporting on the intracranial efficacy of tucatinib given alongside trastuzumab and capecitabine in patients with HER2-positive metastatic breast cancer and brain metastases (5:12).

Read transcript

Have your say on Medicine Matters

Visit the conference hub

Image Credits